secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001628280-25-039883
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra Q2 net revenue $25.9M, net income $74.7M on PRV sale; adjusted net loss $3.2M
--------------------------------------------------------------------------------

- Product net revenue $21.8M (MIPLYFFA $21.5M, OLPRUVA $0.3M) vs $4.4M total revenue in Q2 2024.
- Closed sale of PRV for $150.0M on April 1, boosting cash to $217.7M as of June 30.
- Non-cash impairment of OLPRUVA intangible assets $58.7M and inventory obsolescence $11.7M.
- Adjusted net loss $(3.2)M ($(0.06)/share) excluding PRV sale and impairment charges.
- MIPLYFFA launch: 7 new enrollment forms in Q2, total 129 since launch; market access 52%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000162828025039883/0001628280-25-039883-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000162828025039883/zvra-20250812.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-039883

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer